论文部分内容阅读
背景与目的对于局部晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)同步放化疗是推荐的标准治疗。理想的化疗方案并未确立。本研究拟回顾性分析紫杉醇/卡铂(paclitaxel/carboplatin,PC)三周方案同步胸部放疗治疗局部晚期NSCLC的疗效和安全性,并与标准的依托泊苷/顺铂(cisplatin/etoposide,PE)方案进行比较。方法回顾性分析北京协和医院2012年1月-2014年6月收治的局部晚期NSCLC患者共43例,其中15例接受PC三周方案同步胸部放疗,28例接受PE方案同步胸部放疗。比较两组患者的临床特征、疗效和不良反应。结果全组患者:客观缓解率(objective response rate,ORR)为41.9%,疾病控制率(disease control rate,DCR)为90.7%,中位无疾病进展生存时间(progression-free survival,PFS)为10.6个月(95%CI:7.4-13.8),中位总生存期(overall survival,OS)为19.2个月(95%CI:15.3-23.1)。PC组和PE组在疗效上无统计学差异(ORR:33.3%vs 46.4%,DCR:86.7%vs 92.9%,P=0.638;PFS:6.6个月vs 12.2个月,P=0.389;OS:16.1个月vs 22.1个月,P=0.555)。不良反应可处理,两组均未发生治疗相关死亡。结论PC三周方案同步胸部放疗治疗局部晚期NSCLC与标准PE方案疗效相似,不良反应可接受,在临床中可采用。
Background and Objective Concurrent chemoradiation is the recommended standard of care for locally advanced non-small cell lung cancer (NSCLC). The ideal chemotherapy is not established. This study was to retrospectively analyze the efficacy and safety of a three-week paclitaxel / carboplatin (PC) regimen combined with chest radiotherapy in the treatment of locally advanced NSCLC. The efficacy and safety of standard paclitaxel / carboplatin (PC) Program to compare. Methods A total of 43 patients with locally advanced NSCLC admitted to Peking Union Medical Hospital Hospital from January 2012 to June 2014 were retrospectively analyzed. Among them, 15 received PC thoracic radiation combined with thoracic radiation and 28 received PE thoracic radiation. The clinical characteristics, efficacy and adverse reactions of the two groups were compared. Results All patients had an objective response rate (ORR) of 41.9%, a disease control rate (DCR) of 90.7%, and a median progression-free survival (PFS) of 10.6 Months (95% CI: 7.4-13.8) and a median overall survival (OS) of 19.2 months (95% CI: 15.3-23.1). There was no significant difference in efficacy between the PC and PE groups (ORR: 33.3% vs. 46.4%, DCR: 86.7% vs 92.9%, P = 0.638; PFS: 6.6 months vs 12.2 months, P = 0.389; OS: 16.1 Month vs 22.1 months, P = 0.555). Adverse reactions were manageable, and no treatment-related death occurred in either group. Conclusion PC three weeks program concurrent chest radiotherapy for the treatment of locally advanced NSCLC with standard PE regimen has similar efficacy and adverse reactions are acceptable and can be used clinically.